Thalassaemia, aplastic anaemia, haemophilia, ITP, sickle cell disease and clotting disorders — non-cancerous blood conditions that deserve the same specialist attention as blood cancer. Dr. Basudev Pokhrel. CION Cancer Clinics, Hyderabad.
Thalassaemia is one of the most common inherited blood disorders in Telangana and Andhra Pradesh. Most families don't receive clear information about what it means — or what can be done about it — until a crisis occurs.
Dr. Basudev Pokhrel explains all three forms and what they mean for your family
Thalassaemia is an inherited condition where the body produces abnormal haemoglobin — the protein in red blood cells that carries oxygen. Depending on how many gene defects are inherited, thalassaemia ranges from a symptom-free carrier state to a severe lifelong illness.
Two abnormal genes inherited. Severe anaemia from early childhood. Requires lifelong blood transfusions every 3–4 weeks. Without proper treatment, causes severe organ damage. With regular transfusions and iron chelation, most patients can live well into adulthood — but the burden is enormous. Allogeneic BMT from a matched sibling can offer a cure for eligible young patients.
Intermediate severity — may not require regular transfusions but causes symptoms. Often diagnosed later in childhood or adolescence. Requires regular haematological monitoring, iron chelation when needed and careful management of complications.
One abnormal gene — usually no symptoms. Often discovered on a routine blood count that shows mild anaemia not responding to iron. No treatment needed. Critical importance: if both parents carry the trait, each pregnancy has a 25% risk of thalassaemia major. Pre-pregnancy screening can prevent this entirely.
If you or your partner has thalassaemia minor and are planning a family: Both partners need haemoglobin electrophoresis testing before conception. If both are carriers, prenatal diagnosis (chorionic villus sampling at 10–12 weeks) can detect thalassaemia major in the foetus. This is not optional information — it is life-changing for the child who would be born.
"థాలసేమియా మైనర్ ఉన్న ఇద్దరు జంటలు, పిల్లలు పుట్టడానికి ముందు తప్పనిసరిగా పరీక్ష చేయించుకోవాలి."
Both partners with thalassaemia minor must be tested before planning a pregnancy. Dr. Basudev Pokhrel counsels families in Telugu, Hindi and English — so that nothing is lost in translation when it matters most.
For thalassaemia major in young children with a matched sibling donor, allogeneic bone marrow transplant offers the genuine possibility of cure — eliminating the need for lifelong transfusions entirely. In low-risk young patients (under 7 years, minimal organ damage, good compliance with chelation), long-term cure rates above 85% are reported from major centres.
The critical window is age. Early transplant — before iron overload has caused liver, heart and endocrine damage — gives the best outcomes. Every year of delay in assessment is a year of transfusions and cumulative iron overload that increases transplant risk.
If your child has thalassaemia major and has a sibling: bring the complete records, bring the sibling for HLA typing, and let's assess this properly. Don't wait until the child is older and organ damage makes transplant more difficult.
A significant number of Dr. Basudev's thalassaemia patients travel from districts across Telangana and Andhra Pradesh to Hyderabad for specialist care. He consults in Telugu and understands the practical realities — the distance, the cost of regular transfusions and the lack of access to haematology expertise in smaller cities. If you're coming from outside Hyderabad, WhatsApp ahead with the relevant reports and we will ensure the consultation is comprehensive so you don't need to make a second trip unnecessarily.
Dr. Basudev's JIPMER training in Immunohaematology and Blood Transfusion gives him specific depth in non-malignant blood disorders that many haematologists — focused primarily on blood cancer — don't routinely manage.
Bone marrow failure — the marrow stops producing blood cells. In severe aplastic anaemia, all three cell lines are affected: red cells (anaemia), white cells (infection risk) and platelets (bleeding risk). Severe aplastic anaemia is a haematological emergency. For young patients with a matched sibling donor, allogeneic BMT is the treatment of choice with long-term survival above 80%. For patients without a suitable donor or older patients, immunosuppressive therapy with horse anti-thymocyte globulin (ATG) and cyclosporine achieves responses in 60–70% of patients.
Haemophilia A (Factor VIII deficiency), Haemophilia B (Factor IX deficiency) and von Willebrand disease are inherited bleeding disorders requiring lifelong management. Factor replacement therapy, prophylaxis to prevent joint bleeds and management of acute bleeding episodes — including in surgical settings — are the core of management. Dr. Basudev's immunohaematology training gives him specific expertise in factor product selection, inhibitor management (when patients develop antibodies to factor concentrates) and extended half-life prophylaxis regimens.
ITP is an autoimmune condition where the immune system attacks platelets — causing low platelet counts and increased bleeding risk. Most newly diagnosed patients respond to first-line treatment: steroids (prednisolone or dexamethasone), or IVIG for urgent cases requiring rapid platelet increase before procedures. Second-line options for refractory ITP include thrombopoietin receptor agonists (eltrombopag, romiplostim), rituximab, fostamatinib and splenectomy. Most patients achieve lasting remission with appropriate treatment.
Sickle cell disease is caused by abnormal haemoglobin S that causes red cells to assume a sickle shape, blocking small blood vessels and causing painful vaso-occlusive crises. Sickle cell disease in Telangana and AP is underdiagnosed and undertreated — many patients manage acute crises at local hospitals without comprehensive haematological care. Dr. Basudev manages hydroxyurea therapy (which reduces sickling episodes significantly), crisis management, vaccination and infection prevention, transfusion management and — for selected young patients — BMT evaluation for curative intent.
Red blood cells being destroyed faster than they can be produced — haemolytic anaemia has many causes. Autoimmune haemolytic anaemia (AIHA) — where the immune system attacks red cells — responds to steroids and second-line agents including rituximab and azathioprine. Hereditary spherocytosis, G6PD deficiency, hereditary elliptocytosis and paroxysmal nocturnal haemoglobinuria (PNH) each require specific diagnostic and management approaches. Haemolysis that doesn't have an obvious cause needs haematological evaluation — not watchful waiting.
Deep vein thrombosis (DVT), pulmonary embolism and inherited thrombophilias (Factor V Leiden, Prothrombin mutation, Protein C/S deficiency, antithrombin deficiency) require haematological assessment for anticoagulation decisions and recurrence risk. Antiphospholipid syndrome — an autoimmune clotting disorder that also causes recurrent pregnancy loss — needs specialist management. These conditions are managed chronically in a haematologist's clinic — not just at acute presentation in an emergency department.
In almost all cases, no — thalassaemia minor (also called thalassaemia trait) does not require treatment. People with thalassaemia minor typically live completely normal lives with no significant health problems. You may have a mild anaemia that shows on blood tests, but this does not need iron supplements — in fact, taking unnecessary iron when you have thalassaemia trait can be harmful. The reason I emphasise thalassaemia minor is entirely about family planning. If your partner also carries thalassaemia trait, each pregnancy has a 25% chance of producing a child with thalassaemia major, which is a serious lifelong condition. If you're planning a pregnancy, please bring your partner for haemoglobin electrophoresis testing. This one test can change the trajectory of your child's life.
Yes — for eligible patients. Allogeneic bone marrow transplant from a matched sibling donor offers the genuine possibility of cure, eliminating the need for lifelong blood transfusions. The best outcomes are in young children — ideally under 7 years of age — before iron overload from years of transfusions has caused damage to the liver, heart and endocrine organs. In low-risk young patients with a matched sibling, long-term cure rates above 85% are reported in well-established transplant centres. The critical decision is timing — delay means accumulated iron damage that increases transplant risk. If your child has thalassaemia major and has a sibling, please don't wait to have a transplant assessment. Contact me at +91 9063490160.
Every blood transfusion delivers iron into the body — and the human body has no natural mechanism to excrete excess iron. In thalassaemia major, the iron from years of transfusions accumulates in the liver, heart, pancreas and other organs, causing progressive damage. Iron chelation therapy uses drugs — deferasirox (oral, once daily), deferoxamine (injected) or deferiprone (oral, three times daily) — to bind excess iron and allow it to be excreted through urine or stool. Chelation is as critical as the transfusions themselves. Poorly chelated patients develop heart failure, liver disease and endocrine failure that significantly reduce life expectancy. Good chelation compliance is one of the most important things a family of a thalassaemia major patient can do.
Most thalassaemia major patients require blood transfusions every 3–4 weeks — approximately 13–15 transfusions per year. The goal is to maintain a pre-transfusion haemoglobin above 9–10 g/dL to allow normal growth, activity and organ function. Each transfusion typically involves 10–15 mL/kg of packed red cells given over 2–4 hours. With modern transfusion and chelation, most patients with well-managed thalassaemia major can complete education, work and lead meaningful lives. But the cumulative burden — the hospital visits, the venous access, the chelation compliance, the cost — is enormous for families. This is why BMT evaluation for eligible young patients should happen early.
Treatment for aplastic anaemia depends on severity and whether a matched donor is available. For severe aplastic anaemia in a child with a matched sibling — allogeneic BMT is the treatment of choice. Outcomes are excellent — long-term survival above 80% in young patients with matched sibling donors. If there's no matched sibling, immunosuppressive therapy with horse anti-thymocyte globulin (hATG) and cyclosporine is the first approach — achieving responses in 60–70% of patients. Second-line options include a second course of ATG, eltrombopag (thrombopoietin agonist that has shown remarkable responses in refractory aplastic anaemia) and unrelated donor or haploidentical BMT for non-responders. Aplastic anaemia in a child needs urgent haematologist assessment — not watchful waiting.
Haemophilia is an inherited bleeding disorder where one of the clotting factors is deficient — Factor VIII in Haemophilia A (more common) or Factor IX in Haemophilia B. The severity depends on the factor level — severe haemophilia causes spontaneous bleeding into joints and muscles without any injury. Treatment involves factor replacement — infusing the missing factor to stop or prevent bleeding. Modern management includes prophylaxis — regular preventive factor infusions to keep levels high enough to prevent spontaneous bleeds, protecting the joints. Inhibitor development — where patients develop antibodies against the factor concentrate — is the most challenging complication, requiring bypass agents or emicizumab (a bispecific antibody that mimics Factor VIII activity). Dr. Basudev's immunohaematology training specifically includes bleeding disorder management.
Low platelet count (thrombocytopenia) has many causes — viral infections, medications, nutritional deficiencies, liver disease, lupus, leukaemia, and ITP (immune thrombocytopenia). ITP is specifically an immune-mediated cause where the immune system attacks platelets — it's a diagnosis made by excluding other causes. A haematologist evaluates the platelet count in the context of the full blood count, peripheral blood smear, clinical history and selected tests to determine the cause. ITP is very treatable — most patients respond to steroids, and the majority of newly diagnosed patients achieve remission. But first, the diagnosis needs to be confirmed — a low platelet count on a blood test is a reason to see a haematologist, not to start treatment without a diagnosis.
Yes — sickle cell disease is inherited. Like thalassaemia, it follows an autosomal recessive pattern — both parents must carry the sickle cell trait to have a child with sickle cell disease. If both parents carry the trait, each pregnancy has a 25% chance of producing a child with sickle cell disease, 50% chance of a carrier, 25% chance of unaffected. Regarding cure: for selected young patients with a matched sibling donor, allogeneic BMT can cure sickle cell disease — with long-term disease-free survival above 90% in low-risk children at experienced centres. Gene therapy approaches are currently in advanced clinical trials and may offer a curative option without needing a matched donor in the future. For patients who are not BMT candidates, hydroxyurea therapy remains the most evidence-based disease-modifying treatment — reducing painful crises, acute chest syndrome and hospitalisation significantly.
Dr. Basudev Pokhrel at CION Cancer Clinics, Hyderabad, specialises in thalassaemia management — including transfusion management, iron chelation, genetic counselling for families and BMT assessment for eligible young patients. He consults in Telugu, Hindi and English. He sees a significant number of patients travelling from districts across Telangana and Andhra Pradesh. Located at ANR Centre, 3rd Floor, Banjara Hills, Hyderabad. Contact +91 9063490160 or WhatsApp ahead with your reports.
Yes — diagnosis and management of deep vein thrombosis, pulmonary embolism and inherited thrombophilias is fully available in Hyderabad. The decision about anticoagulation — which drug, what dose, for how long — requires a haematologist's assessment, especially in complex cases involving cancer-associated thrombosis, antiphospholipid syndrome, inherited thrombophilias or recurrent events. Dr. Basudev manages both acute anticoagulation decisions and long-term thrombophilia management. Contact +91 9063490160.
The ongoing cost of thalassaemia major management in Hyderabad depends on transfusion frequency and chelation regimen. Blood transfusions in hospitals cost approximately ₹2,000–5,000 per visit including the blood unit and administration. Iron chelation with oral deferasirox costs approximately ₹3,000–8,000 per month depending on dose and brand. Generic versions are significantly more affordable. Some state government programmes provide transfusion support at reduced or no cost. Allogeneic BMT for thalassaemia major has an upfront cost of ₹15–25 lakh but eliminates the ongoing cost of transfusions and chelation entirely for patients who achieve cure — making it cost-effective over a lifetime for young patients. At my first consultation, I discuss the complete cost picture so families can make informed decisions.
If there's a family history of thalassaemia — or if you've been told you carry the trait — both you and your partner should have haemoglobin electrophoresis testing before planning a pregnancy. This test clearly identifies whether each of you is a carrier. If both of you are carriers: pre-implantation genetic testing (PGT) during IVF or prenatal diagnosis (chorionic villus sampling at 10–12 weeks of pregnancy) can identify whether the foetus has thalassaemia major. These options allow families to make informed decisions about the pregnancy. This is not a dramatic recommendation — it's straightforward preventive care that can spare a child from a lifetime of blood transfusions. Please come for a pre-pregnancy counselling consultation. I consult in Telugu, Hindi and English, and I will explain everything clearly.
Telugu, Hindi and English spoken. Patients from districts across Telangana and AP welcome. WhatsApp your reports ahead and we'll ensure your consultation is comprehensive.